However, the company is expected to benefit from the sales
of new products which are likely to partially offset the weakness in other areas.
Cost-saving efforts are expected to help margins during the quarter. Updates on
the company’s new product launches and approvals for new indications are areas
to keep an eye out for.
In the first quarter of 2019, Teva beat earnings estimates but revenues missed expectations. Revenues fell 15% to $4.3 billion while adjusted EPS dropped 36% to $0.60. Revenues decreased in all geographic regions. Generic products and Copaxone saw sales declines across all markets.
For the full year of 2019, Teva has guided for revenues in
the range of $17-17.4 billion and adjusted EPS in the range of $2.20-2.50.
Teva’s shares have dropped 50% year-to-date and 17% over the past one month. The majority of analysts have rated the stock Hold and it has a price target of $10.75.